Panelist in this video:
+ Dr Alagumurugan Alagarswamy, VP & Head-R&D, Maiva Pharma (Moderator)
+ Dr Rakesh Kumar Bhasin, VP and Head R&D (Formulations), Biocon Pharma
+ Dr Sumedha Nadkar, Site head and Sr Director, Perrigo Labs
+ Dr Pirthi Pal Singh, VP, Tirupati Group
Key Highlights:
● COVID-19 has affected each one of us and even in these unprecedented times, we have been at the forefront responding to the challenges and bringing new therapies to continue to thrive in the changing business scenario: Alagumurugan Alagarswamy, VP & Head – R&D, Maiva Pharma
● The rapid development of novel vaccines for COVID-19 demonstrates that a new type of streamlining and efficiency is indeed possible: Rakesh Kumar Bhasin, VP and Head R&D (Formulations), Biocon Pharma
● The demand for cough and cold medicines actually went down during the pandemic, while the drugs for pain, inflammation and dehydration saw a surge in sales: Dr Sumedha Nadkar, Site head and Sr Director, Perrigo India Laboratories
● 3D printing has a lot of potential for drug delivery: Pirthi Pal Singh, VP, Tirupati Group